Financial News

Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ:GILD)

111.78 +0.03 (+0.03%)
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 7, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
60 61 Next >
Based on good technical signals, GILEAD SCIENCES INC is potentially setting up for a breakout.
GILEAD SCIENCES INC (NASDAQ:GILD) Reveals Intriguing Technical Aspects. Here's What You Need to Know. 
Via Chartmill
Big Biopharma Trails Behind The Market: JP Morgan's 2025 Outlook on Eli Lilly, Merck, and More
JP Morgan highlights 2025 growth prospects for biopharma, animal health, and specialty pharma stocks. Key picks include Eli Lilly, Zoetis, and Bristol-Myers Squibb. 
Via Benzinga
Gilead Sciences to Present at Upcoming Investor Conference
From Gilead Sciences, Inc.
Via Business Wire
Is Vertex Stock A Sell After Pain Drug Whiffs In Midstage Study?
The company is still planning to move into Phase 3 testing, but analysts doubt the pain drug's future. 
Via Investor's Business Daily
(GILD) - Analyzing Gilead Sciences's Short Interest
Via Benzinga
Is GILEAD SCIENCES INC Ready to Break Out of Its Range?
In-Depth Technical Analysis of GILEAD SCIENCES INC. 
Via Chartmill
$100 Invested In This Stock 20 Years Ago Would Be Worth This Much Today
Via Benzinga
COVID-19 is Not the Same Disease for Everyone
(BPT) - The summer spike in COVID-19 infections, triggered in part by a rise in new variants of the virus, was an unpleasant reminder that COVID-19 is here to stay. As we brace for an anticipated... 
Via Brandpoint
Topics Death
U.S. FDA Grants Breakthrough Therapy Designation to Trodelvy® (sacituzumab govitecan-hziy) for Second-Line Treatment of Extensive-Stage Small Cell Lung Cancer
From Gilead Sciences, Inc.
Via Business Wire
Gilead and Terray Therapeutics Announce Multi-Target Research Collaboration to Discover and Develop Novel Small Molecule Therapies
From Gilead Sciences, Inc.
Via Business Wire
Drug Price Hikes Unsupported By Evidence Cost US $815 Million: ICER Report
ICER's 2023 report highlights five drugs with unsupported price increases, leading to $815 million in excess costs for U.S. payers. Discover key findings and trends. 
Via Benzinga
What Analysts Are Saying About Gilead Sciences Stock
Via Benzinga
Looking At Gilead Sciences's Recent Unusual Options Activity
Via Benzinga
Gilead’s Seladelpar Receives Positive CHMP Opinion for Primary Biliary Cholangitis
From Gilead Sciences, Inc.
Via Business Wire
Gilead Sciences Appoints Dietmar Berger, MD, PhD, as Chief Medical Officer
From Gilead Sciences, Inc.
Via Business Wire
Gilead Unveils New Yearly HIV Injection To Offer Hope for Less Frequent Preventive Dosing
Gilead's once-yearly injectable lenacapavir shows promising results in HIV prevention, with a 96% reduction in infections and plans for regulatory filings by 2027. 
Via Benzinga
Kite’s Yescarta® Only CAR T-Cell Therapy to Show Durable Response and Long-Term Survival After Five Years in Patients With Relapsed/Refractory Non-Hodgkin Lymphomas at ASH 2024
From Gilead Sciences, Inc.
Via Business Wire
Price Over Earnings Overview: Gilead Sciences
Via Benzinga
26 Analysts Assess Gilead Sciences: What You Need To Know
Via Benzinga
Longest Follow-Up Data Reported for Kite’s Tecartus® CAR T-Cell Therapy at ASH 2024 Reinforce Durable Efficacy and Survival Benefits
From Gilead Sciences, Inc.
Via Business Wire
Arcellx And Legend Bio Trade Jabs In Multiple Myeloma. But Only One Pulls Ahead.
The companies held competing events on Sunday to discuss their multiple myeloma treatments. 
Via Investor's Business Daily
Arcellx's Cancer Cell Therapy Shows Deep, Durable Responses With Manageable Safety Profile In Heavily Pretreated Blood Cancer Patients
Arcellx's Phase 2 trial of anito-cel in relapsed multiple myeloma reveals high response rates and manageable safety, with durable patient outcomes. 
Via Benzinga
Kite Presents New Data Underscoring Curative Potential of Yescarta® in Relapsed/Refractory Large B-cell Lymphoma at ASH
From Gilead Sciences, Inc.
Via Business Wire
Gilead and Tubulis Enter Into Exclusive Option and License Agreement to Develop ADC Candidate for Select Solid Tumor Target
From Gilead Sciences, Inc.
Via Business Wire
Gilead Announces New England Journal of Medicine Publication of PURPOSE 2 Results
From Gilead Sciences, Inc.
Via Business Wire
Gilead Unveils Long-Term Data From Seladelpar In Patients With Rare Liver Disease
Gilead shares data from its Phase 3 ASSURE study, showing 81% of PBC patients treated with Livdelzi achieved a composite response with continued safety. 
Via Benzinga
Gilead’s Livdelzi (Seladelpar) Demonstrated a Sustained Efficacy and Long-Term Safety Profile in Management of Primary Biliary Cholangitis
From Gilead Sciences, Inc.
Via Business Wire
Trump's Victory Spurs $50B Corporate Bond Surge As Tax Cut Optimism Drives Borrowing Costs To 25-Year Low
The surge in corporate borrowing is driven by a rally in credit and equity markets, which has pushed borrowing costs to historic lows. 
Via Benzinga
Topics Government
Gilead Prices $3.5 Billion of Senior Unsecured Notes
From Gilead Sciences, Inc.
Via Business Wire
Gilead Presents Full PURPOSE 2 Data Results for Twice-Yearly Lenacapavir for HIV Prevention at HIV Glasgow
From Gilead Sciences, Inc.
Via Business Wire
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
60 61 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.

Use the myMotherLode.com Keyword Search to go straight to a specific page

Popular Pages

  • Local News
  • US News
  • Weather
  • State News
  • Events
  • Traffic
  • Sports
  • Dining Guide
  • Real Estate
  • Classifieds
  • Financial News
  • Fire Info
Terms of Service Privacy Policy
© Copyright 2000-2019 Clarke Broadcasting Corporation. All rights reserved.
Feedback